Loading...

FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640905 25 tests $83
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640906 100 tests $194
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests $405
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining

  1. Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
  2. Transfer 100 µL of cell suspension in 5 mL test tube.
  3. Add 5 µL of fluorochrome conjugated Annexin V.
  4. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 & 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, & 425305), if desired.
  5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
  6. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step.
  7. Analyze by flow cytometry.

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  2. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  3. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  4. Zhang T, et al. 2022. EBioMedicine. 77:103872. PubMed
  5. Dhoonmoon A, et al. 2022. Nat Commun. 13:5063. PubMed
  6. Glynn RA, et al. 2022. J Immunol. 208:371. PubMed
  7. Cao H, et al. 2022. Br J Haematol. 198:155. PubMed
  8. Ugamraj HS, et al. 2022. MAbs. 14:2095949. PubMed
  9. Cao L, et al. 2022. Cell Rep. 40:111156. PubMed
  10. Choi UY, et al. 2022. Cell Rep. 40:111234. PubMed
  11. Kimmerling RJ, et al. 2022. Commun Biol. 5:1295. PubMed
  12. Chen X, et al. 2022. Front Pharmacol. 13:1028692. PubMed
  13. Shahid AM, et al. 2022. PLoS One. 17:e0278209. PubMed
  14. Önel T, et al. 2023. Naunyn Schmiedebergs Arch Pharmacol. :. PubMed
  15. Papakonstantinou A, et al. 2022. Int J Mol Sci. 24: . PubMed
  16. Li J, et al. 2023. J Biol Chem. 299:102875. PubMed
  17. Martinelli M, et al. 2023. iScience. 26:105860. PubMed
  18. Tay HG, et al. 2023. Mol Ther. 31:825. PubMed
  19. Dean BD, et al. 2023. J Immunother Cancer. 11: . PubMed
  20. Lieschke E, et al. 2022. Cell Death Differ. 29:1004. PubMed
  21. Gallego-Murillo JS, et al. 2022. Biotechnol Bioeng. 119:3096. PubMed
  22. Du X, et al. 2023. Nucleic Acids Res. 51:1050. PubMed
  23. Vanoli F, et al. 2023. Oncogenesis. 12:8. PubMed
  24. Lei K, et al. 2023. iScience. 26:106001. PubMed
  25. Ohuchi K, et al. 2023. Biomed Rep. 18:28. PubMed
  26. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  27. Perez GI, et al. 2023. Vaccines (Basel). 11:. PubMed
  28. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  29. Potez M, et al. 2023. Front Oncol. 13:1124272. PubMed
  30. Woodley K, et al. 2023. Nat Commun. 14:2132. PubMed
  31. Quintela M, et al. 2023. Clin Epigenetics. 15:63. PubMed
  32. Quintela M, et al. 2023. Br J Cancer. . PubMed
  33. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  34. Dowling CM, et al. 2021. Sci Adv. 7:. PubMed
  35. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  36. Kim EH, et al. 2020. Elife. 9:00. PubMed
  37. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  38. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  39. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  40. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  41. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  42. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  43. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  44. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  45. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  46. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  47. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  48. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  49. Figueiredo T, et al. 2020. Mol Psychiatry. . PubMed
  50. Lopes-Coelho F, et al. 2021. Front Oncol. 11:656229. PubMed
  51. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  52. Olelewe C, et al. 2022. iScience. 25:104340. PubMed
  53. Kim Y, et al. 2020. J Neurochem. 155:177. PubMed
  54. Hassan MIA, et al. 2021. Comput Struct Biotechnol J. 19:880. PubMed
  55. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  56. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  57. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  58. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  59. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  60. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  61. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  62. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  63. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  64. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  65. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  66. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  67. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  68. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  69. Sun V, et al. 2021. Front Immunol. 12:716661. PubMed
  70. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  71. Kim OV, et al. 2022. iScience. 25:104654. PubMed
  72. Shahzadi SK, et al. 2022. Clin Sci (Lond). 136:181. PubMed
  73. Kolbrink B, et al. 2022. Biochem J. 479:259. PubMed
  74. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  75. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  76. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  77. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  78. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  79. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  80. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  81. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  82. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  83. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  84. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  85. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  86. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  87. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  88. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  89. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  90. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  91. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  92. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  93. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  94. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  95. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  96. O'Connor MJ, et al. 2021. Oncogene. 40:4872. PubMed
  97. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  98. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  99. Schmitz RL, et al. 2021. Cells. 10:. PubMed
  100. Babaei A, et al. 2021. Adv Pharm Bull. 11:361. PubMed
  101. Madala HR, et al. 2020. Cancer Res. 3492:80. PubMed
  102. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  103. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  104. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  105. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  106. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  107. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  108. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  109. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  110. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  111. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  112. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  113. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  114. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  115. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  116. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  117. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  118. Müller I, et al. 2020. Mol Cell. 970:77. PubMed
  119. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  120. Norkin M, et al. 2021. Cell Rep. 35:109026. PubMed
  121. Krauss PL, et al. 2021. Front Immunol. 12:730672. PubMed
  122. Zhu Y, et al. 2022. Clin Transl Med. 12:e887. PubMed
  123. Khatib JB, et al. 2022. Oncotarget. 13:1078. PubMed
  124. Matsuda K, et al. 2021. Cell Rep Methods. 1:100122. PubMed
  125. Vanoli F, et al. 2021. Oncogene. 40:5095. PubMed
  126. Liu H, et al. 2021. J Immunother Cancer. 9:. PubMed
  127. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  128. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  129. Meyer N, et al. 2021. J Clin Med. 10:. PubMed
  130. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  131. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  132. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  133. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  134. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  135. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  136. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  137. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  138. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  139. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  140. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  141. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  142. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  143. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  144. Gholamrezaei M, et al. 2021. Iran J Parasitol. 15:475. PubMed
  145. Meyer N, et al. 2021. Int J Mol Sci. 22:. PubMed
  146. Kolbrink B, et al. 2022. Cell Mol Life Sci. 79:387. PubMed
  147. Ishida M, et al. 2021. Int J Mol Sci. 22:. PubMed
  148. Lee DH, et al. 2020. Circ Res. 127:1182. PubMed
  149. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  150. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  151. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  152. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  153. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  154. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  155. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  156. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  157. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  158. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  159. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  160. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  161. Nastasi C, et al. 2021. Sci Rep. 11:1458. PubMed
  162. Molinar-Inglis O, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  163. Erdogan M, et al. 2022. Chem Biodivers. 19:e202200659. PubMed
  164. Shadboorestan A, et al. 2022. Iran J Basic Med Sci. 25:506. PubMed
  165. Huang Y, et al. 2022. Front Cell Dev Biol. 9:837777. PubMed
  166. Babaei A, et al. 2020. Daru. 28:555. PubMed
  167. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  168. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  169. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  170. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  171. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  172. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  173. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  174. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  175. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  176. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  177. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  178. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  179. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  180. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  181. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  182. Huang YL, et al. 2020. Elife. 9:00. PubMed
  183. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  184. Bahl S, et al. 2021. Cell Death Dis. 12:469. PubMed
  185. Jackson LM, et al. 2021. Nucleic Acids Res. 49:12855. PubMed
  186. Tatangelo V, et al. 2022. Front Oncol. 12:877495. PubMed
  187. Alcon C, et al. 2021. Cells. 10:. PubMed
  188. Cao H, et al. 2021. Nat Commun. 12:1792. PubMed
  189. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  190. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  191. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  192. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  193. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  194. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  195. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  196. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  197. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  198. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  199. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  200. Bostanabad SY, et al. 2021. Sci Rep. 11:1539. PubMed
  201. Monzen S, et al. 2022. Mol Clin Oncol. 16:19. PubMed
  202. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  203. Wu J, et al. 2021. Adv Sci (Weinh). 8:e2101029. PubMed
  204. Tu Z, et al. 2022. Cell Rep. 40:111072. PubMed
  205. Bensberg M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  206. Paparella AS, et al. 2021. Nat Commun. 12:6285. PubMed
  207. Huang YL, et al. 2021. iScience. 24:103168. PubMed
  208. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  209. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  210. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  211. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  212. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  213. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  214. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  215. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  216. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  217. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  218. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  219. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  220. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  221. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  222. He J, et al. 2017. FASEB J. 31:2893. PubMed
  223. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  224. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  225. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  226. Bottardi S, et al. 2020. Exp Hematol. 68:88. PubMed
  227. Kasikara C, et al. 2021. J Clin Invest. 131:. PubMed
  228. Ning N, et al. 2022. Theranostics. 12:5537. PubMed
  229. Wang Y, et al. 2022. Front Cardiovasc Med. 9:876087. PubMed
  230. Shankman LS, et al. 2021. Curr Biol. 31:2469. PubMed
  231. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  232. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  233. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  234. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  235. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  236. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  237. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  238. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
  239. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  240. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  241. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  242. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  243. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
RRID
AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
Annexin V
Specificity Alt (DOES NOT SHOW ON TDS):
Annexin V
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 7    Revision Date: 10/22/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account